Effervescent tablets dissolve upon contact with water to

release carbon dioxide and create a drink. We design and

manufacture effervescent tablets that have a pleasant taste, even
if they contain bitter, sulfuric, sour, metallic, astringent, or difficult-
to-process APIs. All our effervescent products dissolve quickly and
completely leaving no residues or foam.

The composition of our effervescent tablets helps to speed

up the absorption of APIs, so they are already dissolved when
entering the body. By creating a buffered solution that increases
the pH value of the stomach, APIs are then quickly passed to the
small intestine. Our effervescent tablets are extremely stable,
meaning they are less sensitive to humidity and high temperatures
and can be used in tropical regions (climatic zones III- IV).
Co-codamol 30/500mg Effervescent Tablets
 Each tablet contains 30mg codeine phosphate
hemihydrate and 500mg paracetamol.

Codeine is indicated in patients older than 12

years of age for the treatment of acute moderate pain which
is not considered to be relieved by other analgesics such as
paracetamol or ibuprofen (alone).

For oral administration only. The tablets should

be dissolved in at least half a tumbler of water before
taking.
The duration of treatment should be limited to
3 days and if no effective pain relief is achieved the
patients/carers should be advised to seek the views of a
physician.
 Adults
One to two tablets dissolved in water not more frequently than every
4 hours to a maximum of 8 tablets in 24 hours.
 Paediatric Population
Children 16-18 years:
One to two tablets every 6 hours when necessary to a maximum of
8 tablets in 24 hours
 Children 12-15 years of age.
One tablet dissolved in water every 6 hours when necessary to a
maximum of 4 tablets in 24 hours.
 Children aged less than 12 years:
Codeine should not be used in children below the age of 12 years
because of the risk of opioid toxicity due to the variable and unpredictable
metabolism of codeine to morphine (see sections 4.3 and 4.4).
 Elderly
A reduced dose may be required.
Dosage is adjusted according to a patient's response and the
severity of the pain, however tolerance to codeine may develop with
prolonged use and care should be taken as adverse effects are dose
related.
 Codeine is a centrally acting weak analgesic. Codeine exerts
its effect through μ opioid receptors, although codeine has low affinity
for these receptors, and its analgesic effect is due to its conversion to
morphine. Codeine, particularly in combination with other analgesics
such as paracetamol, has been shown to be effective in acute
nociceptive pain.

Paracetamol is rapidly and well absorbed from the

intestinal tract after it has left the stomach.
Codeine is absorbed from the gastro-intestinal tract
and peak plasma-codeine concentrations are found in about one
hour.
 Plasma protein binding is low and paracetamol is
metabolised in the liver .
Codeine is metabolised by O- and N- demethylation in
the liver to morphine, norcodeine, and other metabolites including
normorphine and hydrocodone.

Mainly, paracetamol is excreted in the urine as

glucuronide and sulphate conjugates. The elimination half-life is 1-3
hours.
Codeine and its metabolites are excreted almost
entirely by the kidney, mainly as conjugates with glucuronic acid. The
elimination half-life has been reported to be between 3 and 4 hours.
 Sodium hydrogen carbonate
 Citric acid anhydrous

 Sodium carbonate Povidone

 Simeticone

 Sodium saccharin

 Aspartame

 Polysorbate 80
 3 years

Do not store above 25°C. Store in the original

package.

Blister Strips: 41 g/sqm Glassine Paper / 17.25

g/sqm Polyethylene Foil / 9 micron Aluminium foil /
35.50 g/sqm Polyethylene Foil assembled into an
outer carton.
Pack sizes: 30, 32, 56, 60, 84, 90 and 100
tablets.
 an opportunity for formulators to improve the
taste;
 a more gentle action on a patient's stomach;

 marketing aspects (fizzy tablets may have more

consumer appeal than traditional dosage
forms).
 larger tablets
 a complex production process

 very often, the need for specialist packaging

materials.
 Delicate packaging process
 https://www.medicines.org.uk/emc/product/2
126/smpc
 http://www.pharmtech.com/effervescent-
dosage-manufacturing